GRAL Investor Alert: HBSS Probes GRAIL, Inc. (GRAL) Following Securities Class Action Over Failed NHS-Galleri Trial

Hagens Berman is investigating GRAIL, Inc. for allegedly misleading investors about its NHS-Galleri cancer screening trial. The company failed to disclose that a three-year follow-up period was insufficient to meet the trial's primary endpoint. When GRAIL revealed the trial failure on February 19, 2026, its stock collapsed 50.55%, erasing $2.2 billion in market capitalization. The class action period spans May 13, 2025 to February 19, 2026, with a lead plaintiff deadline of August 4, 2026.